<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20210501051142N4</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2022-10-26</date_registration>
      <primary_sponsor>Arak University of Medical Sciences</primary_sponsor>
      <public_title>Evaluation of the effect of crocus sativus tea on anxiety level</public_title>
      <acronym></acronym>
      <scientific_title>Evaluation of the effect of crocus sativus tea on anxiety level of nurses working in intensive care units</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2022-10-02</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>68</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/65378</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Supportive, Randomization description: Nurses are divided into an intervention group and a control group based on the order of entry and the randomization sequence that is established in advance. The sequence is unpredictable and the arrangement is completely random. To allocate the samples, the block randomization method with the size of 6 blocks of 4 blocks will be used, so that by using the random number generation software in the block method, the randomization sequence will be produced according to the required sample size for two groups. At first, the sequence ABAB, ABBA, BBAA, BABA, BAAB, AABB is produced, then randomly and by placing among the blocks, a block is selected and the arrangement pattern in that block will be used to allocate nurses, then this block is placed in the main container and Another block will be selected again. All this will be done with software called Sealed Envelope. With this method, concealment will also be observed. The concept of concealment is to unpredictably assign individuals to groups that the researcher will not be able to predict which group the next person will be in, Blinding description: The data analyzer and participants will not know how the samples are placed in the intervention and control groups.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Anxiety level.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: The intervention group is given tea containing 100 mg of saffron and 100 ml of water for 40 days. At the beginning of the study, demographic questionnaire and Spiel Berger questionnaire are completed by nurses. Based on the response to the Spiel Berger questionnaire, the level of primary anxiety of nurses is determined. Then, at the end of 40 days, the Spiel Berger questionnaire is completed again by the nurses, and all the dependent variables of the research are checked at the beginning and the end of the study, and according to the articles that have measured the level of anxiety with the Spiel Berger questionnaire, in this study, the level Overt anxiety is checked. Intervention 2: Control group: The control group was given a placebo containing 100 ml of water and two drops of saffron essential oil to flavor the water in such a way that it cannot be identified with the tea containing saffron for 40 days. The essential oil used was prepared by Magnolia Company, which is the largest company in the production of flavorings and essential oils in Iran, which started its activity in 2013. At the beginning of the study, demographic questionnaire and Spiel Berger questionnaire are completed by nurses. Based on the response to the Spiel Berger questionnaire, the level of primary anxiety of nurses is determined. Then, at the end of 40 days, the Spiel Berger questionnaire is completed again by the nurses, and all the dependent variables of the research are checked at the beginning and the end of the study, and according to the articles that have measured the level of anxiety with the Spiel Berger questionnaire, in this study, the level Overt anxiety is checked.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
Only the part of the data related to the original outcome will be able to be shared.

When:
since the winter of 2023

To whom:
Researchers and students in this field

Conditions:
In order to reduce the level of anxiety of the medical staff

Where to obtain:
Vice chancellor for education and research, Arak university of medical sciences

How to obtain:
These documents will be available on the website of Arak university of medical sciences.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Mahbobeh Sajadi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>University complex of the Great prophet, Basij square, Sardasht.</address>
        <city>Arak</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>3819693345</zip>
        <telephone>009886341735057</telephone>
        <email>golmehrsherafati@gmail.com</email>
        <affiliation>Arak University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Mahbobeh Sajadi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>University complex of the Great prophet, Basij square, Sardasht.</address>
        <city>Arak</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>3819693345</zip>
        <telephone>009886341735057</telephone>
        <email>golmehrsherafati@gmail.com</email>
        <affiliation>Arak University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Nurses who attend the ward only for 175 hours per month (mandatory hours).
Not taking any sedative and anti-anxiety drugs</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>65 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Unwillingness to participate in the study
Allergic to saffron
Complications caused by the consumption of saffron
The presence of any underlying disease
Pregnancy</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>F41.9</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Anxiety disorder, unspecified</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Other</i_code>
      <i_code>Other</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: The intervention group is given tea containing 100 mg of saffron and 100 ml of water for 40 days. At the beginning of the study, demographic questionnaire and Spiel Berger questionnaire are completed by nurses. Based on the response to the Spiel Berger questionnaire, the level of primary anxiety of nurses is determined. Then, at the end of 40 days, the Spiel Berger questionnaire is completed again by the nurses, and all the dependent variables of the research are checked at the beginning and the end of the study, and according to the articles that have measured the level of anxiety with the Spiel Berger questionnaire, in this study, the level Overt anxiety is checked.</i_keyword>
      <i_keyword>Control group: The control group was given a placebo containing 100 ml of water and two drops of saffron essential oil to flavor the water in such a way that it cannot be identified with the tea containing saffron for 40 days. The essential oil used was prepared by Magnolia Company, which is the largest company in the production of flavorings and essential oils in Iran, which started its activity in 2013. At the beginning of the study, demographic questionnaire and Spiel Berger questionnaire are completed by nurses. Based on the response to the Spiel Berger questionnaire, the level of primary anxiety of nurses is determined. Then, at the end of 40 days, the Spiel Berger questionnaire is completed again by the nurses, and all the dependent variables of the research are checked at the beginning and the end of the study, and according to the articles that have measured the level of anxiety with the Spiel Berger questionnaire, in this study, the level Overt anxiety is checked.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Anxiety rate. Timepoint: Before the intervention and 40 days after the start of the first intervention, the anxiety level of each patient is measured. Method of measurement: At the beginning and end of the study, the demographic questionnaire and the Spiel Berger questionnaire were completed by the nurses of both groups and based on this, the anxiety level of nurses is determined.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Arak University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2022-05-15</approval_date>
        <contact_name>Ethics committee of Arak university of medical sciences</contact_name>
        <contact_address>Arak university of medical sciences, Basij Sq., Sardasht region Arak Markazi Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
